Rilutek, with its active ingredient riluzole, is a medication primarily used in the management of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. ALS is a progressive neurodegenerative disorder that affects nerve cells in the brain and the spinal cord, leading to loss of muscle control. Rilutek works by modulating glutamate signaling in the brain. Glutamate is a neurotransmitter that, when present in excessive amounts, can contribute to the death of nerve cells. By reducing the release of glutamate, Rilutek is believed to slow down the progression of the disease and extend survival. However, it is not a cure for ALS and does not reverse the damage already done to motor neurons. It is typically administered orally and can have side effects, including nausea, dizziness, and liver function abnormalities, among others. Regular monitoring by a healthcare provider is recommended for patients on this medication.